Francesco Franchi
Overview
Explore the profile of Francesco Franchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
1862
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ortega-Paz L, Rollini F, Franchi F, Sibbing D, Angiolillo D
Interv Cardiol Clin
. 2024 Dec;
13(4S):e1-e30.
PMID: 39674676
Antiplatelet therapy involving aspirin and a P2Y receptor inhibitor is fundamental in managing patients with atherothrombotic disease. Switching between P2Y inhibitors is frequently observed in clinical settings for various reasons,...
2.
Angiolillo D, Galli M, Alexopoulos D, Aradi D, Bhatt D, Bonello L, et al.
JACC Cardiovasc Interv
. 2024 Nov;
17(22):2639-2663.
PMID: 39603778
Current evidence indicates that dual antiplatelet therapy with aspirin plus a P2Y inhibitor is essential for the prevention of thrombotic events after percutaneous coronary interventions. However, dual antiplatelet therapy is...
3.
Occhipinti G, Ortega-Paz L, Franchi F, Rollini F, Capodanno D, Brugaletta S, et al.
Expert Opin Drug Metab Toxicol
. 2024 Oct;
21(1):29-40.
PMID: 39407420
Introduction: Cangrelor, the only intravenous platelet P2Y receptor inhibitor, is characterized by a prompt and potent platelet inhibition, with a rapid offset of action. Large-scale clinical trials have shown that...
4.
5.
Ortega-Paz L, Franchi F, Rollini F, Galli M, Been L, Ghanem G, et al.
JACC Basic Transl Sci
. 2024 Aug;
9(7):865-876.
PMID: 39170956
This prospective ex vivo and in vitro pharmacodynamic (PD)/pharmacokinetic investigation was conducted in patients with diabetes mellitus with (n = 31) and without chronic kidney disease (n = 30). PD...
6.
Cavallari L, Lee C, Franchi F, Keeley E, Rossi J, Thomas C, et al.
Clin Transl Sci
. 2024 Aug;
17(8):e70004.
PMID: 39150361
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is indicated after percutaneous coronary intervention (PCI) to reduce the risk of atherothrombotic events. Approximately...
7.
Galli M, Occhipinti G, Ortega-Paz L, Franchi F, Rollini F, Brugaletta S, et al.
Drugs
. 2024 Jul;
84(9):1055-1070.
PMID: 39073551
Significant advancements have shaped the landscape of anticoagulant therapy in the past two decades, including the introduction of direct oral anticoagulants (DOACs), characterized by favorable safety and efficacy profiles and...
8.
AlSaeed M, Thomas C, Franchi F, Keeley E, Duarte J, Gong Y, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(5):1227-1230.
PMID: 39031256
The ABCD-GENE score was developed to predict poor response to clopidogrel and includes Age, Body mass index, Chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m),...
9.
10.
Tunehag K, Thomas C, Franchi F, Rossi J, Keeley E, Anderson R, et al.
J Am Heart Assoc
. 2024 Jun;
13(12):e033791.
PMID: 38874073
Background: Cytochrome P450 2C19 (CYP2C19) intermediate and poor metabolizer patients exhibit diminished clopidogrel clinical effectiveness after percutaneous coronary intervention (PCI). However, outcome studies to date have lacked racial diversity. Thus,...